Close
Smartlab Europe
Inizio Ignite

Drug Research

Syndax and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases

Syndax Pharmaceuticals, Inc. and Incyte announced that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax’s anti-CSF-1R monoclonal antibody. “This partnership has the potential to significantly expand and maximize the axatilimab program...

Union therapeutics signs deal with Innovent to develop orismilast in China

Union therapeutics has signed a strategic partnership and license agreement with Innovent Biologics to develop and commercialise its therapy, orismilast, in China. A potent and selective next-generation PDE4 inhibitor for inflammatory dermatology conditions, orismilast possesses extensive anti-inflammatory properties. Developed originally by...

InSilicoTrials and Galileo Research announce their partnership

Innovation and cutting-edge technology to reduce Research and Development time and costs: InSilicoTrials, a company with broad expertise in Computational Modeling and Simulation, IT and cloud solutions for the healthcare sector, and Galileo Research established a partnership to apply...

Velocity Clinical Research’s multi-site acquisitions signal new frontier for clinical site management industry

Velocity Clinical Research announces it has acquired two multi-site companies, VitaLink Research and the National Research Institute, for an undisclosed amount. The double acquisition adds 11 sites to Velocity’s existing 18, making it the largest fully integrated site management...

FDA Approves Samsung Bioepis and Biogens BYOOVIZ, LUCENTIS Biosimilar

Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i , for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO),...

Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance

Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd. announced a strategic alliance. Under the terms of the agreement, BBL will offer approximately...

Frontage Expands Early Drug Discovery Services through the Acquisition of Heyan Biotech

Frontage Shanghai announced the acquisition of 70% equity interest in Wuhan Heyan Biomedical Technology Co., Ltd. Heyan Biotech, located in Wuhan Optics Valley, national biotech industry base, provides for target based in vitro pharmacodynamic screening and early pharmacological pharmacodynamic...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »